Trending: Moderna to Develop Cancer Vaccine With Merck, Gets FDA OK for Kids' Covid Booster
October 12 2022 - 2:58PM
Dow Jones News
14:28 ET -- Moderna Inc. is one of the most talked about
companies in the U.S. across all news items in the last 12 hours,
according to Factiva data. Early Wednesday, Merck said it will
exercize an option to collaborate with Moderna on a personalized
cancer vaccine, where it will pay Moderna $250 million for the
joint development and future commercialization of the vaccine.
Later Wednesday morning, Moderna said it has received FDA
authorization for its Omicron-targeting bivalent Covid-19 booster
vaccine in children and teens 6 to 17 years of age. Dow Jones &
Co. owns Factiva. (susan.solan@wsj.com)
(END) Dow Jones Newswires
October 12, 2022 14:43 ET (18:43 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Sep 2023 to Sep 2024